Lexaria Non Current Liabilities Total from 2010 to 2024

LEXXW Stock  USD 0.80  0.05  6.67%   
Lexaria Bioscience Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total is likely to outpace its year average in 2024. During the period from 2010 to 2024, Lexaria Bioscience Non Current Liabilities Total regression line of quarterly data had mean square error of 2 B and geometric mean of  41,034. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2005-11-30
Previous Quarter
115.3 K
Current Value
109.3 K
Quarterly Volatility
364.8 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 125.2 K or Other Operating Expenses of 3.2 M, as well as many indicators such as Price To Sales Ratio of 105, Dividend Yield of 0.0 or PTB Ratio of 54.87. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Lexaria Non Current Liabilities Total Regression Statistics

Arithmetic Mean65,363
Geometric Mean41,034
Coefficient Of Variation85.14
Mean Deviation41,852
Median49,657
Standard Deviation55,651
Sample Variance3.1B
Range208.6K
R-Value0.64
Mean Square Error2B
R-Squared0.41
Significance0.01
Slope7,948
Total Sum of Squares43.4B

Lexaria Non Current Liabilities Total History

2024209.8 K
2023109.3 K
2022136.2 K
2021 7401.0
202050 K
2019120.1 K
201831.5 K

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total109.3 K209.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.